Hans Hull
Known title: Chief Business OfficerCIK: 0001614876
Associated companies
Transaction History
| PLRX | ▲ Buy | Grant | 40,150 | $0 | 1/23/2025 | View on chart |
| PLRX | ▼ Sell | Open Market | 15,936 | $179K | 1/17/2025 | View on chart |
| PLRX | ▼ Sell | Open Market | 9,900 | $114K | 7/10/2024 | View on chart |
| PLRX | ▲ Buy | Grant | 19,337 | $0 | 7/9/2024 | View on chart |
| PLRX | ▲ Buy | Grant | 31,500 | $0 | 1/23/2024 | View on chart |
| PLRX | ▼ Sell | Open Market | 9,786 | $169K | 1/17/2024 | View on chart |
| PLRX | ▲ Buy | Option Exercise | 8,791 | $18K | 8/4/2023 | View on chart |
| PLRX | ▼ Sell | Open Market | 20,050 | $401K | 8/4/2023 | View on chart |
| PLRX | ▼ Sell | Open Market | 13,069 | $261K | 8/3/2023 | View on chart |
| PLRX | ▲ Buy | Option Exercise | 1,800 | $4K | 8/3/2023 | View on chart |
| PLRX | ▼ Sell | Open Market | 1,800 | $36K | 8/3/2023 | View on chart |
| PLRX | ▼ Sell | Open Market | 17,937 | $323K | 7/17/2023 | View on chart |
| PLRX | ▲ Buy | Grant | 35,156 | $0 | 7/14/2023 | View on chart |
| PLRX | ▼ Sell | Open Market | 9,036 | $240K | 3/30/2023 | View on chart |
| PLRX | ▲ Buy | Grant | 17,578 | $0 | 3/29/2023 | View on chart |
| PLRX | ▲ Buy | Grant | 54,000 | $0 | 1/25/2023 | View on chart |
| PLRX | ▼ Sell | Open Market | 8,748 | $167K | 12/20/2022 | View on chart |
| PLRX | ▲ Buy | Grant | 17,578 | $0 | 12/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Pliant Therapeutics Names New Chief Medical Officer
Pliant Therapeutics has appointed David Raben, M.D., as its new Chief Medical Officer. This leadership change is a standard corporate update for the company. The stock is currently trading within its 52-week range, with recent technical indicators showing a support rejection near $1.13.
Pliant Therapeutics Names New Chief Medical Officer. Pliant Therapeutics has appointed David Raben, M.D., as its new Chief Medical Officer. This leadership change is a standard corporate update for the company. The stock is currently trading within its 52-week range, with recent technical indicators showing a support rejection near $1.13.